Table 3.
Cost effectiveness estimates of olmesartan medoxomil versus other angiotensin II receptor antagonists. Estimates are based on treatment for 5 years in a hypothetical cohort of 100 000 individuals. Incremental benefits (events avoided) were calculated using Framingham models and the absolute reductions in diastolic blood pressure at 8 weeks in a clinical trial comparing the four agents (Simons 2003)
| Cost of cardiovascular disease or accident avoided ($US) | Incremental benefit of using olmesartan medoxomil (events avoided) | Total incremental economic benefit of olmesartan medoxomil ($US1000) | |||||
|---|---|---|---|---|---|---|---|
| Versus losartan | Versus valsartan | Versus irbesartan | Versus losartan | Versus valsartan | Versus irbesartan | ||
| Cardiovascular disease | 25 165 | 602 | 645 | 215 | 15 149 | 16 231 | 5140 |
| Coronary heart disease | 29 229 | 380 | 409 | 136 | 11 107 | 11 955 | 3975 |
| Myocardial infarction | 16 625 | 244 | 271 | 86 | 4057 | 4505 | 1430 |
| Stroke | 13 814 | 104 | 126 | 36 | 1437 | 1741 | 497 |
| Death from cardiovascular disease | NA | 65 | 80 | 12 | NA | NA | NA |
| Death from coronary heart disease | NA | 66 | 80 | 15 | NA | NA | NA |
Abbreviations: NA, not available.